Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.
- Sector: Healthcare
- Industry: Biotechnology
- Full Time Employees: 76
- Incorporated in 2019
- Headquartered in Radnor, Pennsylvania
- https://mineralystx.com
Ticker: NASDAQ:MLYS
IPO: Feb 10, 2023
No comments:
Post a Comment